6-OAU is primarily researched for its potential therapeutic applications in metabolic and inflammatory diseases. It acts as a GPR84 agonist, a receptor involved in immune response and metabolism, making it a candidate for treating conditions like obesity, diabetes, and non-alcoholic fatty liver disease. Studies suggest it may improve insulin sensitivity and reduce inflammation, offering a promising avenue for drug development. Additionally, its role in modulating immune cell activity could be leveraged in managing autoimmune disorders or chronic inflammatory conditions. Research is ongoing to explore its efficacy and safety in these areas.